Cytomegalovirus: Time for a requiem?

Blood

Volumn 111, Issue 11, 2008, Pages 5265-5266

  Mehta, Jayesh ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAVIR; CIDOFOVIR; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; VALACICLOVIR; VALGANCICLOVIR;

ALLOGENIC BONE MARROW TRANSPLANTATION; BONE MARROW SUPPRESSION; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG MECHANISM; DYSGEUSIA; ENZYME INHIBITION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HUMAN; INFECTION RISK; NAUSEA; NEPHROTOXICITY; NONHUMAN; NOTE; PRIORITY JOURNAL; VARICELLA ZOSTER VIRUS; VIREMIA; VIRUS INFECTION;

EID: 61849155122     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-142521     Document Type: Note

References (7)

1. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991;325:1601-1607.
2. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl I Med. 1991;324:1005-1011.
3. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88:4063-4071.
4. Singhal S, Mehta J, Powles R. Prevention of cytomega-lovirus disease by a short course of preemptive ganciclovir of foscarnet. Blood. 1994;84:2055.
5. Mehta J, Powles R. The future of bone marrow transplantation. In: Atkinson K, ed. Clinincal Bone Marrow and Blood Stem Cell Transplantation, second edition. Cambridge, Cammbridge University Press, 2000:1457-1465.
6. Lalezari JP, Aberg JA, Wang LH, et al. Phase I does escalation trial evaluating the pharmacokinetics, antihuman cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother. 2002;46:2969-2976.
7. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell taransplantation with virus-specific T-cell lines. Lancet. 2003;362:1375-1377.